Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026

Jazz Pharmaceuticals (JAZZ)

Nasdaq Health Care Pharmaceuticals S&P MidCap 400
$234.76
+7.44 (+3.27%)
Close of Nov 06, 2026 · end-of-day data
Source: Jazz Pharmaceuticals's 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 03, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$1.49B$1.62B$1.89B$2.16B$2.36B$3.09B$3.66B$3.83B$4.07B$4.27B
Research & development$162.30M$198.44M$226.62M$299.73M$335.38M$505.75M$590.45M$849.66M$884.00M$782.74M
Selling, general & admin$502.89M$544.16M$683.53M$736.94M$854.23M$1.45B$1.42B$1.34B$1.39B$1.81B
Operating income$591.65M$528.84M$614.84M$532.37M$378.07M$170.28M-$65.53M$578.58M$716.63M-$430.24M
Interest expense$27.50M$37.80M$56.70M$62.50M$87.60M$89.90M$32.80M$32.80M——
Pre-tax income$532.45M$441.12M$529.46M$454.30M$275.10M-$112.84M-$372.78M$297.93M$470.35M-$627.86M
Income tax$135.24M-$47.74M$80.16M-$73.15M$33.52M$216.12M-$158.65M-$119.91M-$91.43M-$272.44M
Net income$396.83M$487.85M$447.10M$523.37M$238.62M-$329.67M-$224.06M$414.83M$560.12M-$356.15M
EBITDA$603.45M$541.94M$630.04M$547.67M$396.77M$196.98M-$35.23M$608.98M$749.43M-$388.64M
EPS (basic)$6.56$8.13$7.45$9.22$4.28$-5.52$-3.58$6.55$9.06$-5.84
EPS (diluted)$6.41$7.96$7.30$9.09$4.22$-5.52$-3.58$6.10$8.65$-5.84
Diluted shares61.87M61.32M61.22M57.55M56.52M59.69M62.54M72.07M66.01M60.98M
Operating margin39.8%32.7%32.5%24.6%16.0%5.5%-1.8%15.1%17.6%-10.1%
Net margin26.7%30.1%23.6%24.2%10.1%-10.7%-6.1%10.8%13.8%-8.3%

Balance sheet

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$365.96M$386.04M$309.62M$637.34M$1.06B$591.45M$881.48M$1.51B$2.41B$1.39B
Receivables$234.24M$224.13M$263.84M$355.99M$396.49M$563.36M$651.49M$705.79M$716.76M$830.70M
Inventory$34.05M$43.24M$52.96M$78.61M$95.40M$1.07B$714.06M$597.04M$480.44M$417.00M
Total current assets$748.07M$968.28M$1.23B$1.63B$2.84B$2.61B$2.61B$3.44B$4.63B$4.17B
Goodwill$893.81M$947.54M$927.63M$920.02M$958.30M$1.83B$1.69B$1.75B$1.72B$1.83B
Total assets$4.80B$5.12B$5.20B$5.54B$6.54B$12.30B$10.84B$11.39B$12.01B$11.66B
Total current liabilities$257.41M$293.95M$345.49M$364.49M$653.75M$809.30M$933.19M$1.54B$1.04B$2.24B
Short-term debt$36.09M$40.60M$33.39M$33.39M$246.32M$31.00M$31.00M$604.95M$31.00M$1.03B
Long-term debt$1.99B$1.54B$1.56B$1.57B$1.85B$6.02B$5.69B$5.11B$6.08B$4.33B
Total debt$2.03B$1.58B$1.60B$1.61B$2.09B$6.05B$5.72B$5.71B$6.11B$5.36B
Total liabilities$2.92B$2.41B$2.45B$2.43B$2.88B$8.33B$7.75B$7.66B$7.92B$7.34B
Shareholders' equity$1.88B$2.71B$2.76B$3.11B$3.66B$3.97B$3.09B$3.74B$4.09B$4.32B

Cash flow

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow$592.39M$693.09M$798.90M$776.40M$899.65M$778.51M$1.27B$1.09B$1.40B$1.36B
Capital expenditures$9.69M$28.95M$20.37M$40.13M$15.00M$27.64M$29.05M$23.96M$38.07M$58.75M
Free cash flow$582.70M$664.14M$778.53M$736.27M$884.64M$750.87M$1.24B$1.07B$1.36B$1.30B
Investing cash flow-$1.75B-$268.95M-$394.49M-$155.30M-$1.01B-$5.21B-$446.23M-$163.06M-$508.19M-$1.51B
Financing cash flow$540.99M-$409.11M-$479.13M-$293.75M$528.07M$3.97B-$529.49M-$305.25M$20.52M-$873.38M
Share buybacks$278.30M$98.80M$523.67M$301.45M$146.54M$0$54.00K$269.76M$311.43M$125.02M
Stock-based compensation$98.77M$106.90M$102.44M$110.56M$121.00M$189.01M$222.00M$226.84M$248.04M$291.13M
Depreciation & amortization$11.80M$13.10M$15.20M$15.30M$18.70M$26.70M$30.30M$30.40M$32.80M$41.60M

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.